ClinicalTrials.gg

Program

CDX-622

A development code.

Its studies are mostly in Asthma, led by Celldex Therapeutics.

Furthest: phase 1, since Oct 18, 20242 company-led studies, 1 open or runningNext primary completion: Mar 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Celldex Therapeutics21 open or runningphase 1since Oct 18, 2024Oct 18, 2024Mar 2027phase 1 · NCT07330778

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 18, 2024First study: phase 1 study in Healthy ParticipantsFirst studyNCT06650761 · 85 enrolled · United States
  2. Sep 26, 2025Phase 1 study in AsthmaNCT07330778 · 12 planned · United States

Ahead

  1. Mar 2027Primary completion: phase 1 study in AsthmaNCT07330778

TargetBeta

KITLG →TSLP →read by rule
“CDX-622 is a bispecific antibody that binds to stem cell factor (SCF) and thymic stromal lymphopoietin (TSLP).”study text, by rule · the study

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07330778Asthma · United States1RecruitingMar 202712
NCT06650761Healthy Participants · United States1CompletedApr 24, 202685

How it is read

Names in the registry

  • “CDX-622”, 2 entries

Codes read as this program: CDX622.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.